Research press release


Nature Medicine

Arthritis drug may help combat kidney disease


常染色体優性多発性嚢胞腎(ADPKD)は腎臓に嚢胞が形成されるのが特徴の病気で、原因はポリシスチン-1とポリシスチン-2というタンパク質の遺伝子の変異である。R Liたちは、ADPKD患者の嚢胞液中に存在する炎症誘発性シグナルタンパク質、腫瘍壊死因子-α(TNF-α)が、細胞膜と一次繊毛へのポリシスチン-2の蓄積を阻害することを明らかにした。



A drug currently used to treat rheumatoid arthritis could be used to treat people with a genetic kidney disease reports a study published online this week in Nature Medicine.

Autosomal dominant polycystic kidney disease (ADPKD), a condition characterized by the formation of cysts in the kidneys, is caused by mutations in the genes that encode the proteins polycystin-1 and -2. Rong Li and colleagues show that tumour necrosis factor-alpha (TNF-alpha), an inflammatory signalling protein present in the cystic fluid of humans with ADPKD, disrupts the accumulation of polycystin-2 to the cell membrane and primary cilia.

Giving TNF-alpha to mice susceptible to developing cysts, owing a mutation in the gene coding for polycystin-2, resulted in the intensification of disease. By contrast, treatment of the same mice with the TNF-alpha inhibitor etanercept, which is used to treat rheumatoid arthritis, prevented cyst formation.

These data reveal a pathway connecting TNF-alpha, the polycystins and cystogenesis, and suggest that etanercept might be useful to treat people with ADPKD.

doi: 10.1038/nm1783


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。